Conference Perspectives

View all perspectives
      OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs

      >1/2 D2T RA pts starting JAKi

      Mrinalini Dey DrMiniDey

      3 months 2 weeks ago
      OP0137 is comparative analysis of clinical efficacy & drug retention of b/tsDMARDs >1/2 D2T RA pts starting JAKi, RTX, IL-6Ri, or TNFi, but ~1/3 w abatacept, achieved remission or low disease activity in 6m & maintained consistent drug retention for 2yrs @RheumNow #EULAR2024
      Top 3 Messages About JAK Inhibitor Safety
      3 months 2 weeks ago
      RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. Al

      Dr. John Cush RheumNow

      3 months 2 weeks ago
      RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & our Faculty.
      Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies i

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      Synovial tissue specimens were processed for H&E-based semiquantitative synovitis quantification (KSS) in biopsies in PsA. KSS was significantly higher in cs/b-DMARDs resistant patients than naive PsA(p<0.0001) and PsA in remission/LDA (p<0.0001). KSS directly correlated with… https://t.co/cHIw8zRByK https://t.co/vppmG7JwC8
      In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150 @RheumNow https://t.co/vC4pgSKmfY
      Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively?

      VACIMRA (multicentre 🇫🇷) showed

      David Liew drdavidliew

      3 months 2 weeks ago
      Is it worthwhile delaying MTX start for a month in RA, to vaccinate effectively? VACIMRA (multicentre 🇫🇷) showed it marginally improves pneumococcal vaccine immunogenicity, persisting to 1y, no extra pred needed. I’ll admit, I’m still not game! #EULAR2024 OP0140 @RheumNow https://t.co/58qJxki8ov
      How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis?

      E

      David Liew drdavidliew

      3 months 2 weeks ago
      How can we predict the 1/3 of palindromic rheumatism patients who will go on to develop persistent inflamm arthritis? Easy to use score derived from 15y data from @UniversityLeeds - can exclude the low-risk so they don’t need to be followed. #EULAR2024 OP0127 @RheumNow https://t.co/gB0FpUPOFC
      OP0131 on occurrence & predictors of #DMARD treatment failure in #RA

      8% of pts failed ≥3 b/tsDMARDs with ~4yrs to

      Mrinalini Dey DrMiniDey

      3 months 2 weeks ago
      OP0131 on occurrence & predictors of #DMARD treatment failure in #RA 8% of pts failed ≥3 b/tsDMARDs with ~4yrs to failure In pts starting first b/tsDMARD, up to 25% fail ≥2 b/tsDMARDs in 3yrs Risk of fulfilling EULAR D2T criterion 1 ➡️ 2.3% in first 5yrs @RheumNow #EULAR2024
      🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA

      📈Female sex, high jo

      Mrinalini Dey DrMiniDey

      3 months 2 weeks ago
      🗣️Abstract session on difficult-to-treat #RA kicks off with OP0118 on predictors of D2T RA 📈Female sex, high joint count, erosions, pulmonary #comorbidities, depression & fatigue assoc with D2T RA 💊MTX after start of advanced therapy protective of D2T RA @RheumNow #EULAR2024
      #EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in childre

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in children & adults. One in 6 lost response in subsequent cycle due to antidrug antibodies. Humanised or type 2 antiCD20Ab in the future could improve this @RheumNow https://t.co/duYpr2yKGB
      #EULAR2024 OP0077 How can we improve Bcell killing and does deep depletion matter? Biomarkers from RCT showed Obinutuzum

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 months 2 weeks ago
      #EULAR2024 OP0077 How can we improve Bcell killing and does deep depletion matter? Biomarkers from RCT showed Obinutuzumab led to profound circulatory depletion in #lupus nephritis & those w sustained depletion had better complete renal response than those who didn’t @RheumNow https://t.co/2KTZBR2njk
      GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexp

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      GC treatment duration for <90 and 90 to 360 days is associated with a higher risk of cumulative SI compared to nonexposed, especially the first year but also up to two years since first visit in RA patients. Maximum RR for <90 days is observed at 8 months since first visit (RR:… https://t.co/ecK2ylqrRk https://t.co/IQ5QQjExYQ
      Poster tours at #EULAR2024.
      A third of seropositive RA patients with long disease duration had subclinical lung abnormal

      Dr. Antoni Chan synovialjoints

      3 months 2 weeks ago
      Poster tours at #EULAR2024. A third of seropositive RA patients with long disease duration had subclinical lung abnormalities. This pilot study showed the potential role of lung ultrasound for the screening of subclinical ILD among these patients. Abstract 070 @RheumNow https://t.co/ypAh4idV3j
      Who needs intensive therapy in #lupus

      Intensive Rx in #SLE from 2 inception cohorts in Leeds
      Either #Cyclo or #biologi

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      Who needs intensive therapy in #lupus Intensive Rx in #SLE from 2 inception cohorts in Leeds Either #Cyclo or #biologics ⬆️ If low complement Within 2 yrs after #dx #SLEDAI >9 AntiRo+ OP0187 #EULAR2024 @RheumNow @eular_org https://t.co/oKhwMmHhSs
      Top 3 messages
      Re
      #JAKi #safety

      Shared decision w benefit/risk info

      Some #CV risks are more Impt than others- stratify

      Janet Pope Janetbirdope

      3 months 2 weeks ago
      Top 3 messages Re #JAKi #safety Shared decision w benefit/risk info Some #CV risks are more Impt than others- stratify your pt into risk categories #Smoking is a big risk for #MACE & #malignancy-So work on facilitating Smoking #cessation #EULAR2024 @eular_org @RheumNow

      Podcasts

      • Which One Is The Loneliest Number (9.27.2024)
      • I Cant Treat Ugly (9.20.2024)
      • Systemic Sclerosis Insights (9.13.2024)

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.